Abstract: Advances in Treatment: Virtual Reality Cue Exposure for the Treatment of SUDs (Society for Social Work and Research 28th Annual Conference - Recentering & Democratizing Knowledge: The Next 30 Years of Social Work Science)

All in-person and virtual presentations are in Eastern Standard Time Zone (EST).

SSWR 2024 Poster Gallery: as a registered in-person and virtual attendee, you have access to the virtual Poster Gallery which includes only the posters that elected to present virtually. The rest of the posters are presented in-person in the Poster/Exhibit Hall located in Marquis BR Salon 6, ML 2. The access to the Poster Gallery will be available via the virtual conference platform the week of January 11. You will receive an email with instructions how to access the virtual conference platform.

Advances in Treatment: Virtual Reality Cue Exposure for the Treatment of SUDs

Schedule:
Friday, January 12, 2024
Liberty Ballroom I, ML 4 (Marriott Marquis Washington DC)
* noted as presenting author
Micki Washburn, PhD, Assistant Professor, UTA School of Social Work, Arlington
LaTisha Thomas, MSW, LCSW-S, Doctoral Student, The University of Texas at Arlington, Arlington, TX
Suzanne Brown, PhD, Associate Professor, Wayne State University, Detroit, MI
Substance use disorders (SUDs) are chronic, recurring conditions that if left untreated, pose a significant and ongoing public health and safety threat. 1-5 Craving, a strong repeated urge or desire to use substances, is one of the most salient components of SUDs.6-10 Virtual reality cue exposure (VRCE) has shown promise in addressing substance craving.11-16 This oral presentation will present data from a group of substance use treatment professionals and individuals in sustained recovery who tested and evaluated a new VR based digital therapeutic for the treatment for SUDs.

High levels of craving are associated with continued substance use and put individuals in recovery at risk of relapse. Craving is most frequently evoked by exposure to environmental stimuli, termed “substance use cues” which are associated with one’s prior substance use. VRCE places individuals with a history of substance use in controlled virtual environments mirroring their “in vivo” use environments, safely exposing them to their most salient substance use cue, allowing them to practice skills such as substance refusal and management of craving. As users in the virtual environments experience craving without the ability to engage in actual substance use, these exposures weaken the relationship between substance use cues and actual substance use.15-17

The newly created HelixVR digital therapeutic has significant potential for improving patient care and reducing health disparities. The prototype of HelixVR was tested with a group of substance use treatment providers (n = 12) and a group of individuals in recovery (n = 11) to evaluate the acceptability, feasibility, and usability of the product. User testing was followed up by virtual focus groups asking additional questions about participants’ experiences using HelixVR including ease of use, what they did and did not like, applicability to their client population, and how feasible it would be to implement Helix VR as a part of residential and outpatient treatment.

Data were collected on participants’ experiences of presence and immersion, usability, substance craving, simulator sickness and their overall comfort with using technology.18-19 Independent t-tests were conducted to investigate the difference in scales/subscales between different user types (peer vs. therapist), gender (female vs. male), and race (White vs. black, indigenous, and other people of color - BIPOC). Individuals in recovery rated HelixVR higher in interface quality, a subscale of Presence Questionnaire, and rated it higher in cognitive Involvement. BIPOC participants scored higher in adaptation, a subscale of Presence Questionnaire, meaning they felt more like they were a part of the virtual environment than non-BIPOC participants. The evaluation of system usability was conducted using the System Usability Scale118 and the levels of usability for the HelixVR digital therapeutic scored in the 88 percentile, indicating above average performance. Qualitative data from the development and product testing established the feasibility and acceptability of this VR based tool as well as ease of integration into usual substance use treatment workflows through the implementation of therapist-and self-administered mobile/web-based platform. Implications for substance use treatment and education will be offered.